February 2017February 2017
New Product - Cerdelga
Cerdelga (eliglustat) is a potent and specific inhibitor of glucosylceramide synthase, and acts as a substrate reduction therapy for Gaucher disease type 1 (GD1). The goal of this approach is to reduce the rate of synthesis of glucosylceramide to match its impaired rate of catabolism in patients with GD1, thereby preventing glucosylceramide accumulation and alleviating clinical manifestations. Cerdelga is indicated for the long-term treatment of adults with GD1. Eliglustat is contraindicated in patients who are CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor; and CYP2D6 poor metabolisers (PMs) taking a strong CYP3A inhibitor. Cerdelga is available as capsules containing 84 mg eliglustat (equivalent to 100 mg eliglustat tartrate) in blister packs of 56’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au